If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,548.00    -6.00 (-0.39%)
Bid:
1,544.00
Ask:
1,547.00
Spread: 3.00 (0.194%)
Market Cap: £3.26b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

10 Apr 2025 14:36

RNS Number : 5612E
Hikma Pharmaceuticals Plc
10 April 2025
 

 

Hikma Pharmaceuticals PLC - Discretionary Share Awards

 

LONDON, 10 April 2025: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee made the following conditional awards under the Hikma Pharmaceuticals PLC 2023 Long Term Incentive Plan (the "LTIP") and the 2023 Deferred Bonus Plan (the "DBP") to Persons Discharging Managerial Responsibility ("PDMRs") of the Company. No consideration was paid for the grant of the awards.

Awards under the LTIP were made on 9 April 2025 based on a price of £18.81 per Ordinary Share (being the average mid-market Ordinary Share price for the 5-working day period prior to 9 April 2025, in accordance with the LTIP rules) (the "LTIP Awards"). All LTIP Awards are subject to the continued employment of the PDMR and malus and clawback provisions.

LTIP Performance Share Plan ("PSP") Awards are subject to the satisfaction of performance conditions set by the Remuneration Committee of the Company. The LTIP (PSP) Awards will normally vest on the later of the third anniversary of the date of grant and the determination of the performance conditions. The LTIP (PSP) Awards are then subject to an additional two-year holding period.

LTIP (Conditional) Awards will normally vest on the second anniversary of the date of grant.

Awards under the DBP were made on 9 April 2025 based on a price of £18.81 per Ordinary Share (being the average mid-market Ordinary Share price for the 5-working day period prior to 9 April 2025, in accordance with the DBP rules) (the "DBP Awards"). The vesting of the DBP Awards is subject to the continued employment of the PDMRs, and malus and clawback provisions. The DBP Awards will normally vest on the third anniversary of the date of grant.

 

This notification is made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided in accordance with the requirements of Article 19(3) of MAR.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Executive Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and DBP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 128,501

Nil

DBP Award: 30,783

d)

Aggregated information

Price(s): Nil

Volume(s): 159,284

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Riad Mishlawi

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and DBP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 148,270

Nil

DBP Award: 30,582

d)

Aggregated information

Price(s): Nil

Volume(s): 178,852

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and DBP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 102,554

Nil

DBP Award: 25,864

d)

Aggregated information

Price(s): Nil

Volume(s): 128,418

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 73,559

d)

Aggregated information

Price(s): Nil

Volume(s): 73,559

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 73,620

d)

Aggregated information

Price(s): Nil

Volume(s): 73,620

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Susan Ringdal

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Susan Ringdal

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 38,760

d)

Aggregated information

Price(s): Nil

Volume(s): 38,760

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Hussein Arkhagha

 1

 Details of the person discharging managerial responsibilities / person closely associated

 a)

 Name

 Hussein Arkhagha

 2

 Reason for the notification

 a)

 Position/status

 PDMR

 b)

Initial notification /Amendment

 Initial notification

 3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 a)

 Name

 Hikma Pharmaceuticals PLC

 b)

 LEI

 549300BNS685UXH4JI75

 4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 a)

Description of the financial instrument, type of instrument and identification code

 Description: Ordinary shares of 10 pence each (Shares)

 ID Code: GB00B0LCW083

 b)

Nature of the transaction

 

 Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 46,913

d)

Aggregated information

Price(s): Nil

Volume(s): 46,913

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Bill Larkins

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bill Larkins

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 52,497

d)

Aggregated information

Price(s): Nil

Volume(s): 52,497

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Julie Hill

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Julie Hill

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 29,501

Nil

LTIP (Conditional) Award: 579

d)

Aggregated information

Price(s): Nil

Volume(s): 30,080

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Hafrun Fridriksdottir

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Hafrun Fridriksdottir

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 57,825

d)

Aggregated information

Price(s): nil

Volume(s): 57,825

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

 

 

Helen Middlemist

Group Company Secretary+44 (0) 20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBXGDSSXBDGUG
Date   Source Headline
6th Feb 201712:47 pmRNSHolding(s) in Company
18th Jan 20179:11 amRNSHikma receives approval for Sodium Oxybate
20th Dec 20163:24 pmRNSDirector/PDMR Shareholding
20th Dec 201611:00 amRNSHolding(s) in Company
20th Dec 201610:47 amRNSDirector/PDMR Shareholding
13th Dec 20161:46 pmRNSDirector/PDMR Shareholding
12th Dec 20164:06 pmRNSDirector/PDMR Shareholding
7th Dec 20169:35 amRNSDirector/PDMR Shareholding
6th Dec 20166:04 pmRNSTotal Voting Rights
5th Dec 201612:34 pmRNSDirector/PDMR Shareholding
2nd Dec 20165:42 pmRNSDirector/PDMR Shareholding
28th Nov 20169:59 amRNSDirector/PDMR Shareholding
22nd Nov 20167:00 amRNSHikma announces agreement with Vectura
16th Nov 201611:12 amRNSAdditional Listing
11th Nov 20162:48 pmRNSTotal Voting Rights
10th Nov 20167:00 amRNSTrading Statement
3rd Oct 20164:37 pmRNSBlock listing Interim Review
28th Sep 20165:12 pmRNSDirector/PDMR Shareholding
28th Sep 20169:09 amRNSDirector/PDMR Shareholding
26th Sep 201610:18 amRNSDirector/PDMR Shareholding
22nd Sep 20163:35 pmRNSDirector/PDMR Shareholding
20th Sep 20167:00 amRNSBoard appointment and succession
16th Sep 20165:32 pmRNSDirector/PDMR Shareholding
15th Sep 20164:36 pmRNSDirector/PDMR Shareholding
8th Sep 20165:18 pmRNSDirector/PDMR Shareholding
6th Sep 20165:52 pmRNSDirector/PDMR Shareholding
6th Sep 20164:02 pmRNSTotal Voting Rights
1st Sep 201610:18 amRNSDirector/PDMR Shareholding
26th Aug 20164:28 pmRNSDirector/PDMR Shareholding
26th Aug 20169:47 amRNSDirector/PDMR Shareholding
24th Aug 20167:00 amRNSHalf-year Report
10th Aug 20169:22 amRNSNotice of Results
3rd Aug 20165:18 pmRNSTrading Statement
21st Jul 20167:00 amRNSRegulatory approval of Hikma's colchicine upheld
20th Jul 20167:00 amRNSLaunch of Generic Xeloda® Tablets in the US
27th Jun 20167:01 amRNSDirector/PDMR Shareholding
27th Jun 20167:00 amRNSTotal Voting Rights
20th Jun 20167:00 amRNSDirector/PDMR Shareholding
7th Jun 20164:44 pmRNSTotal Voting Rights
24th May 20167:00 amRNSDirector/PDMR Shareholding
19th May 201612:15 pmRNSFurther re Colchicine Litigation
19th May 201610:17 amRNSDirector/PDMR Shareholding
18th May 20164:25 pmRNSDirector/PDMR Shareholding
12th May 20163:14 pmRNSResult of AGM
12th May 20167:00 amRNSAGM Statement
9th May 20164:05 pmRNSDirector/PDMR Shareholding
6th May 20169:12 amRNSDoc re. Bond Guarantor Group
29th Apr 20165:40 pmRNSDirector/PDMR Shareholding
28th Apr 20162:58 pmRNSDirector/PDMR Shareholding
25th Apr 20164:19 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.